Showing 2681-2690 of 18644 results for "".
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
https://reachmd.com/programs/cme/clinical-implications-of-neoadjuvant-therapy-guideline-updates-in-resectable-melanoma/36323/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Patient-Centric Innovations in MS Care: High-Efficacy DMT’s, Cognition, and Special Patient Populations
https://reachmd.com/programs/cme/patient-centric-innovations-in-ms-care-high-efficacy-dmts-cognition-and-special-patient-populations/29172/Learn more about the use of high-efficacy DMTs in multiple sclerosis.Impact of COS: Gonadotropics and Ovulation Trigger on Oocyte Competence
https://reachmd.com/programs/global-womens-health-academy/impact-of-cos-gonadotropics-and-ovulation-trigger-on-oocyte-competence/9625/Dr. Peter Humaidan presents on LH activity supplementation, differences between LH and hCG, effects of LH on oocyte quality, and more.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-stage-iii-melanoma/36326/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
https://reachmd.com/programs/cme/insights-from-global-key-opinion-leaders-on-regional-regulatory-and-guideline-nuances-to-optimize-melanoma-management/36331/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.The Underestimated Consequences of Uncontrolled Gout: Renal and Cardiovascular Implications
https://reachmd.com/programs/cme/the-underestimated-consequences-of-uncontrolled-gout-renal-and-cardiovascular-implications/15702/Our experts offer tips to rapidly and sustainably lower serum uric acid levels to <6 mg/dL in your patients with CKD & uncontrolled refractory gout.Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
https://reachmd.com/programs/project-oncology/evaluating-axatilimab-in-chronic-gvhd-how-prior-therapies-impact-outcomes/36315/How does treatment history affect response to axatilimab in chronic graft-versus-host disease (cGVHD)? Join Dr. Hallie Blevins as she reviews a post hoc analysis from the AGAVE-201 trial, which evaluated clinical outcomes based on prior exposure to ruxolitinib, belumosudil, and other agents. FindingPrimary Biliary Cholangitis: Shining Light on an "Invisible" Female Health Burden
https://reachmd.com/programs/cme/primary-biliary-cholangitis-shining-light-on-an-invisible-female-health-burden/36709/Review clinical features, diagnostic criteria, and treatment options for PBC, a chronic liver disease primarily affecting women over age 50.Targeting B7-H3 in ES-SCLC: Advancing Targeted Therapy Through Evidence-Based Innovation and Multidisciplinary Care
https://reachmd.com/programs/cme/targeting-b7-h3-in-es-sclc-advancing-targeted-therapy-through-evidence-based-innovation-and-multidisciplinary-care/36232/Explore the rationale and emerging efficacy and safety data for B7-H3–targeted ADCs in ES-SCLC to support patient selection and multidisciplinary care.